AdvaMed® Response to Senate HELP Committee Regarding Reauthorization of Pandemic All-Hazards Preparedness Act

WASHINGTON—AdvaMed, the Medtech Association, the world’s largest organization representing medtech innovators, and the Association of British HealthTech Industries (ABHI), the leading trade association for medical technology companies in the United Kingdom, are calling for reciprocal “zero for zero” tariffs between the two countries and greater regulatory convergence, noting the prominence of medtech in both the U.S. and U.K. health care systems and economies and the critical need to avoid disruptions in patient care that tariffs could cause in both countries.

AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products. 

WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech.

April 25, 2025 – Carbon Medical Technologies, Inc. (CMT), a manufacturer of pyrolytic carbon-coated medical devices used in biopsy procedures, for radiation therapy, and to treat stress urinary incontinence, is proud to announce that our BiomarC Tissue Marker System has successfully achieved certification under the European Union Medical Device Regulation (EU MDR 2017/745).

Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.

Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.

Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the next era of artificial intelligence-enabled medical and digital health technologies to provide patients and clinicians transformative new tools to aid in diagnosis and treatment. 

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.